US4462986A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Synergistic anti-herpes compositions
Assignee: Syntex USA LLC
•
Filing: 1982-11-04
•
Granted: 1984-07-31
•
Expires: 2002-11-04
Abstract
Abstract Combinations of 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl]guanine or a pharmaceutically acceptable salt thereof, and interferon show synergy in their activity against herpes virus infections.
Inventors
- 👤 Kendall O. Smith
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 21:51
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/217; A61P; A61P31/00; A61P31/12
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
64 words
A therapeutic composition having activity against herpes simplex virus types HSV I and HSV II and comprising an effective amount of a composition comprising, in combination, at least one interferon compound in admixture with 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl] guanine or a pharmaceutically acceptable salt thereof, the relative amount of interferon therein being from about 50 to about 500,000 units per microgram of 9-[[2-hydroxyl-1-(hydroxymethyl)ethoxy]methyl] guanine or salt thereof.
Claim 2
Dependent Claim
64 words
A therapeutic composition having activity against herpes simplex virus types HSV I and HSV II and comprising an effective amount of a composition comprising, in combination, at least one interferon compound in admixture with 9-[[2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl] guanine or a pharmaceutically acceptable salt thereof, the relative amount of interferon therein being from about 50 to about 500,000 units per microgram of 9-[[2-hydroxyl-1-(hydroxymethyl)ethoxy]methyl] guanine or salt thereof.
Claim 3
Dependent Claim
15 words
The composition of claim 1 wherein the interferon is interferon-γ, interferon-α, or a mixture thereof.
Claim 4
Dependent Claim
28 words
The composition of claim 2, wherein the relative amount of interferon therein is from about 5000 to about 100,000 units per microgram of 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl] guanine or salt thereof.
Claim 5
Dependent Claim
32 words
A process for treatment of herpes simplex virus types HSV I and HSV II infections in mammals which comprises administering thereto an effective amount of a therapeutic composition according to claim 1.
Claim 6
Dependent Claim
33 words
A process for the treatment of herpes simplex virus types HSV I and HSV II infections in mammals which comprises administering thereto an effective amount of a therapeutic composition according to claim 2.
Claim 7
Dependent Claim
33 words
A process for the treatment of herpes simplex virus types HSV I and HSV II infections in mammals which comprises administering thereto an effective amount of a therapeutic composition according to claim 3.
Claim 8
Dependent Claim
28 words
The composition of claim 2, wherein the relative amount of interferon therein is from about 5,000 to about 40,000 units per microgram of 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl] guanine or salt thereof.
Claim 9
Dependent Claim
33 words
A process for the treatment of herpes simplx virus types HSV I and HSV II infections in mammals which comprises administering thereto an effective amount of a therapeutic composition according to claim 7.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-31 | 1988-01-30 | 1988-07-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-31 | 1992-01-30 | 1992-07-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-31 | 1996-01-30 | 1996-07-31 | $7700.00 | Window Closed / Lapsed |